

## Details phase 3 trials COVID-19 vaccine candidates

	AstraZeneca	Moderna	Pfizer/BioNtech	Janssen	Sanofi*	CureVac*	
<b>Vaccine</b>	AZD1222 5x10 <sup>10</sup> vp	mRNA-1273 100 ug	BNT162b2 RNA 30ug	Ad26.COV2.S 5x10 <sup>10</sup> vp	preS dTM 5 ug	cVnCoV	
<b>Platform</b>	Viral vector	mRNA	mRNA	Viral Vector	Protein subunit	mRNA	
<b>Control</b>	saline	saline	saline	saline			
<b>administration</b>	im	im	im	im	im	im	
<b>Number of participants</b>	Vaccine: 20.000 Control:10.000	Vaccine: 15.000 Control 15.000	Vaccine: 21,999 Control: 21,999	Vaccine: 30.000 Control: 30.000	30-35.000		
<b>Age groups</b>	>18 yrs: 18-65 ≥ 65 (at least 25% of total group)	>18 yrs: ≥ 65, <65 at risk <65 not at risk 25-40% in 2 risk groups	≥16 years: 16-55 yrs >55, at least 40% of total	≥18 - <60 years ≥60 years min 30%. (@20% 18-40 yrs) incl. with comorbidities	>18 years incl. elderly and co-morbidities		
<b>Number of vaccine doses</b>	2 (D1, D29)	2 (D1, D29)	2 (D1, D22)	1	1		
<b>Blood collection</b>	Day 1, 15, 43	Day 1, 29, 57, 209, 394, 759	Day 1, 8, 22, 29, 36. Month 6, 12, 24 post dose2	Day 1, 29, 71, Month 6, 12, 18, 24			
<b>Follow-up</b>	2 years	2 years	2 years	2 years + 1 month			
<b>Primary objective</b>	- VE for prevention of COVID-19, -safety and tolerability	-VE to prevent COVID-19 -safety and reactogenicity	VE at least 7 days after dose 2.	-VE prevention moderate, severe COVID -safety			
<b>Primary endpoint</b>	SARS2 PCR 150 events in not seropositive participants	SARS2 PCR 151 events in not seropositive participants	SARS2 PCR 164 events in not seropositive participants	SARS2 PCR 154 events in not seropositive participants			

	baseline. For VE 60% -(S)AEs	baseline. For VE 60% -(S)AEs	baseline. For VE 60% -(S)AEs	baseline, VE60% -(S)EAs			
<b>Secondary objective</b>	-Prevention of infection -VE different case definitions incl severe COVID	-VE severe COVID, -VE serologically confirmed COVID -immunogenicity	-immunogenicity 360 participants	-prevention infection and mild COVID-19 -immunogenicity			
<b>Secondary endpoint</b>	-seroconversion ab against N -symptoms -b-ab S -Neut ab	Serum bAb levels against SARS-CoV-2 S-, N-protein by ligand-binding assay, nAb		-binding Ab ELISA -Neutr ab			
<b>Interim analysis efficacy</b>	1, after 75 cases with VE 70-75%	2, after 53 and 106 cases with VE >=72%	4, first after 32 cases if VE >=77%	Set of 4 predefined criteria			
<b>First indication VE data available</b>	End Dec 2020	End nov 2020	End Oct 2020				

\* Phase 3 trials not started yet, protocol not finalized